View ValuationQuantum BioPharma 향후 성장Future 기준 점검 0/6현재 Quantum BioPharma 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.핵심 정보n/a이익 성장률n/aEPS 성장률Pharmaceuticals 이익 성장48.7%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트31 Mar 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesChief Financial Officer recently sold CA$55k worth of stock Apr 17Chief Financial Officer recently sold CA$765k worth of stock Apr 09Quantum Biopharma Ltd. Submits Investigational New Drug Application for Lucid-MS Phase Two Clinical Trial in Multiple SclerosisApr 01Quantum Biopharma Intends to Submit an Investigational New Drug Application for Lucid-MS to the U.S. Food and Drug Administration in the Coming WeeksMar 27Quantum Biopharma Ltd. Announces Peer-Reviewed Publication of Clinical Trial Results for UnbuzzdMar 23Co-Founder exercised options to buy CA$94k worth of stock. Mar 19New major risk - Market cap size Mar 12Quantum BioPharma Ltd. announced that it expects to receive CAD 4 million in fundingMar 11+ 1 more updateQuantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)Dec 26Quantum BioPharma Ltd. has filed a Follow-on Equity Offering in the amount of $17.243174 million.Dec 23Quantum BioPharma Ltd. announced that it has received CAD 0.00075 million in funding from Xorax Family Trust, Fortius Research and Trading CorporationDec 12Quantum BioPharma Ltd. has withdrawn its Follow-on Equity Offering in the amount of $21.225 million.Dec 09New major risk - Share price stability Nov 27Chief Financial Officer recently sold CA$512k worth of stock Nov 24Quantum BioPharma Ltd. has filed a Follow-on Equity Offering in the amount of $21.225 million.Nov 01Quantum BioPharma Ltd. announced that it expects to receive CAD 0.00075 million in funding from Xorax Family Trust, Fortius Research and Trading CorporationOct 30Quantum Biopharma Ltd. Receives Final Reports for Two Key Studies of Its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical TrialOct 03Health Canada Grants Quantum BioPharma Ltd. Product License for Its Innovative Product, Qlarity™, That Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive PerformanceSep 18Halo Biopharma Australia Pty Ltd. Signs Agreement to Manufacture Oral Drug Formulation of Its Potential Breakthrough Drug Lucid-21-302 (Lucid-Ms) for Use in Its Upcoming Phase 2 Multiple Sclerosis TrialAug 12Is Quantum BioPharma (CSE:QNTM) Using Too Much Debt?Aug 09New major risk - Financial position Aug 08Quantum Biopharma Ltd. Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis PatientsAug 08Quantum BioPharma Ltd., Annual General Meeting, Sep 26, 2025Aug 07Quantum BioPharma Ltd. Announces Positive Results of the Clinical Study Report for the Phase 1 Multiple Ascending Dose Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)Aug 05Huge Biopharma Australia Pty Ltd. Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United KingdomJul 09Quantum BioPharma Ltd. announced that it expects to receive CAD 0.0006 million in funding from Xorax Family Trust, Fortius Research and Trading CorporationJun 29Quantum BioPharma Ltd. Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General HospitalJun 18iNGENu CRO Partners with Quantum Biopharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS PatientsJun 03Quantum BioPharma Ltd. Receives USD 2.35 Million from A Mutually-Agreed Global Legal Settlement with Dr. Raza BokhariMay 30Quantum Biopharma Ltd. Receives Ethics Committee Approval for Phase 2 Clinical Trial of Fsd202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation SyndromeMay 28New major risk - Financial position May 15Quantum Biopharma Ltd. Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-Ms for Multiple SclerosisMay 12Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari At the Court of Appeal for OntarioApr 14Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple SclerosisApr 01Quantum BioPharma Ltd. announced that it has received CAD 4.9 million in fundingMar 31New major risk - Financial position Mar 28Less than half of directors are independent Mar 28Quantum Biopharma Ltd. Announces Board ChangesMar 27Quantum Biopharma Ltd. Announces Completion of Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302Feb 26Quantum Biopharma Ltd. Announces the Success of Unbuzzd Clinical TrialFeb 04New major risk - Share price stability Dec 22Quantum BioPharma Ltd. announced that it expects to receive CAD 5 million in fundingDec 05New major risk - Financial position Nov 13Quantum BioPharma Regains Nasdaq Listing ComplianceSep 09Quantum Biopharma Announces Celly Nutrition Launches Unbuzzd(Tm) Grab-And-Go Stick Packs on Amazon.Com So You Can "Own Now and What’S Next"Aug 30Quantum BioPharma Ltd. Announces Executive AppointmentsAug 24+ 1 more updateNew major risk - Financial position Aug 15FSD Pharma Announces Share Consolidation, Part of the Company's Plan to Regain Compliance with Nasdaq Minimum Bid Price RequirementAug 13New major risk - Shareholder dilution Aug 09FSD Pharma Inc. Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in AustraliaJun 28New major risk - Market cap size Jun 09FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol IntoxicationJun 05New major risk - Financial position May 16FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in AustraliaMay 08New minor risk - Shareholder dilution Apr 10FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage UnbuzzdMar 12FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis (Actrims) 2024 ForumMar 05FSD Pharma Inc. has filed a Follow-on Equity Offering in the amount of $11.154232 million.Feb 19FSD Pharma Inc. Announces Board ChangesJan 30FSD Pharma Inc. Provides an Update Regarding Its Litigation with GBB Drink Lab, IncJan 18GBB Maintains Strong Position in Its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss CaseJan 12FSD Pharma Inc. announced that it has received CAD 0.000046 million in fundingDec 07FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in fundingNov 29New major risk - Financial position Nov 29FSD Pharma Inc. Announces Change of CEONov 18FSD Pharma Inc. Announces the Ontario Superior Court of Justice Has Dismissed the Motion to Set Aside the Arbitration Award to FSD Pharma Filed by Raza BokhariOct 05FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple SclerosisSep 19FSD Pharma to Present Its Phase 1 Data on Lucid-MS At MSMilan 2023Aug 17New minor risk - Shareholder dilution Aug 13New minor risk - Shareholder dilution Aug 06FSD Pharma Inc. Announces CEO ChangesJul 06Raza Bokhari Files Two Additional Claims Against the FSD Pharma Seeking Relief and Monetary Damages Exceeding $30.2 MillionJun 22FSD Pharma Inc. Announces Board ChangesMay 26Founder recently bought CA$442k worth of stock Apr 13FSD Pharma Regains Compliance with NASDAQ Continued Listing RequirementsFeb 16+ 1 more updateFSD Pharma Inc. Receives Regulatory Clearance for its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug CandidateFeb 08FSD Pharma Inc. Announces Recruiting Is Underway for the Company's Phase 2 Clinical Trial of Fsd201 for the Treatment of Chronic PainJan 31FSD Pharma Inc. Announces Submission of Its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MSJan 20FSD Pharma Inc. Submits Its Phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigationJan 18FSD Pharma Inc. Announces Committee AppointmentsJan 10FSD Pharma Announces Changes to the Board of DirectorsNov 29Less than half of directors are independent Nov 16FSD Pharma Inc. Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza BokhariNov 12FSD Pharma Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencySep 30FSD Pharma Inc. Receives “Study May Proceed” Letter for the Investigational New Drug Application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its Phase 2 Clinical Trial of Fsd201Sep 07FSD Pharma Inc. Elects Fernando Cugliari as DirectorJun 28FSD Pharma Inc. Files Investigational New Drug Application with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory Disorder and Provides Corporate UpdatesJun 01FSD Pharma Inc. Announces Dismissal of Derivative ComplaintMay 08FSD Pharma Inc., Annual General Meeting, Jun 23, 2022May 07Founder recently bought CA$63k worth of stock Apr 27High number of new and inexperienced directors Apr 27FSD Pharma Inc. Appoints David Allan and John Mcgraw to the Company's Advisory BoardApr 22Founder recently bought CA$59k worth of stock Apr 14We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn RateApr 13FSD Pharma Inc. Announces Executive AppointmentsApr 07Founder recently bought CA$54k worth of stock Feb 28An unknown buyer entered into an agreement to acquire Cobourg Facility in Cobourg, Ontario from FSD Pharma Inc. (CNSX:HUGE) for CAD 16.5 million.Feb 26이익 및 매출 성장 예측CNSX:QNTM - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2026N/A-11N/AN/A112/31/2025N/A-26-8-8N/A9/30/2025N/A-29-9-9N/A6/30/2025N/A-27-11-11N/A3/31/2025N/A-21-9-9N/A12/31/2024N/A-14-7-7N/A9/30/2024N/A-10-7-7N/A6/30/2024N/A-7-5-5N/A3/31/2024N/A-10-8-8N/A12/31/2023N/A-18-11-11N/A9/30/2023N/A-23-16-16N/A6/30/2023N/A-29-22-22N/A3/31/2023N/A-31-28-28N/A12/31/2022N/A-27-29-28N/A9/30/2022N/A-27-26-26N/A6/30/2022N/A-25-23-23N/A3/31/2022N/A-30-21-20N/A12/31/2021N/A-34-21-21N/A9/30/2021N/A-32-22-21N/A6/30/2021N/A-39-22-22N/A3/31/2021N/A-30-20-19N/A12/31/2020N/A-28-19-19N/A9/30/2020N/A-36-18-17N/A6/30/2020N/A-35-15-15N/A3/31/2020N/A-41-17-16N/A12/31/2019N/A-34-14-14N/A9/30/20190-38N/A-14N/A6/30/20190-25N/A-19N/A3/31/20190-16N/A-16N/A12/31/2018N/A-17N/A-14N/A9/30/20180-2N/A-11N/A6/30/20180-7N/A-3N/A3/31/20180-4N/A-1N/A12/31/20170-3N/A0N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: QNTM 의 예상 수익 증가율이 절약률(2.9%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: QNTM 의 수익이 Canadian 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: QNTM 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: QNTM 의 수익이 Canadian 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: QNTM 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: QNTM의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 18:59종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Quantum BioPharma Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kumaraguru RajaBrookline Capital MarketsKaren SterlingKingswood Capital
Quantum Biopharma Ltd. Submits Investigational New Drug Application for Lucid-MS Phase Two Clinical Trial in Multiple SclerosisApr 01
Quantum Biopharma Intends to Submit an Investigational New Drug Application for Lucid-MS to the U.S. Food and Drug Administration in the Coming WeeksMar 27
Quantum Biopharma Ltd. Announces Peer-Reviewed Publication of Clinical Trial Results for UnbuzzdMar 23
Quantum BioPharma Ltd. announced that it expects to receive CAD 4 million in fundingMar 11+ 1 more update
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)Dec 26
Quantum BioPharma Ltd. has filed a Follow-on Equity Offering in the amount of $17.243174 million.Dec 23
Quantum BioPharma Ltd. announced that it has received CAD 0.00075 million in funding from Xorax Family Trust, Fortius Research and Trading CorporationDec 12
Quantum BioPharma Ltd. has withdrawn its Follow-on Equity Offering in the amount of $21.225 million.Dec 09
Quantum BioPharma Ltd. announced that it expects to receive CAD 0.00075 million in funding from Xorax Family Trust, Fortius Research and Trading CorporationOct 30
Quantum Biopharma Ltd. Receives Final Reports for Two Key Studies of Its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical TrialOct 03
Health Canada Grants Quantum BioPharma Ltd. Product License for Its Innovative Product, Qlarity™, That Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive PerformanceSep 18
Halo Biopharma Australia Pty Ltd. Signs Agreement to Manufacture Oral Drug Formulation of Its Potential Breakthrough Drug Lucid-21-302 (Lucid-Ms) for Use in Its Upcoming Phase 2 Multiple Sclerosis TrialAug 12
Quantum Biopharma Ltd. Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis PatientsAug 08
Quantum BioPharma Ltd. Announces Positive Results of the Clinical Study Report for the Phase 1 Multiple Ascending Dose Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)Aug 05
Huge Biopharma Australia Pty Ltd. Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United KingdomJul 09
Quantum BioPharma Ltd. announced that it expects to receive CAD 0.0006 million in funding from Xorax Family Trust, Fortius Research and Trading CorporationJun 29
Quantum BioPharma Ltd. Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General HospitalJun 18
iNGENu CRO Partners with Quantum Biopharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS PatientsJun 03
Quantum BioPharma Ltd. Receives USD 2.35 Million from A Mutually-Agreed Global Legal Settlement with Dr. Raza BokhariMay 30
Quantum Biopharma Ltd. Receives Ethics Committee Approval for Phase 2 Clinical Trial of Fsd202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation SyndromeMay 28
Quantum Biopharma Ltd. Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-Ms for Multiple SclerosisMay 12
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari At the Court of Appeal for OntarioApr 14
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple SclerosisApr 01
Quantum Biopharma Ltd. Announces Completion of Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302Feb 26
Quantum Biopharma Announces Celly Nutrition Launches Unbuzzd(Tm) Grab-And-Go Stick Packs on Amazon.Com So You Can "Own Now and What’S Next"Aug 30
FSD Pharma Announces Share Consolidation, Part of the Company's Plan to Regain Compliance with Nasdaq Minimum Bid Price RequirementAug 13
FSD Pharma Inc. Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in AustraliaJun 28
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol IntoxicationJun 05
FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in AustraliaMay 08
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage UnbuzzdMar 12
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis (Actrims) 2024 ForumMar 05
GBB Maintains Strong Position in Its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss CaseJan 12
FSD Pharma Inc. Announces the Ontario Superior Court of Justice Has Dismissed the Motion to Set Aside the Arbitration Award to FSD Pharma Filed by Raza BokhariOct 05
FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple SclerosisSep 19
Raza Bokhari Files Two Additional Claims Against the FSD Pharma Seeking Relief and Monetary Damages Exceeding $30.2 MillionJun 22
FSD Pharma Inc. Receives Regulatory Clearance for its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug CandidateFeb 08
FSD Pharma Inc. Announces Recruiting Is Underway for the Company's Phase 2 Clinical Trial of Fsd201 for the Treatment of Chronic PainJan 31
FSD Pharma Inc. Announces Submission of Its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MSJan 20
FSD Pharma Inc. Submits Its Phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigationJan 18
FSD Pharma Inc. Receives “Study May Proceed” Letter for the Investigational New Drug Application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its Phase 2 Clinical Trial of Fsd201Sep 07
FSD Pharma Inc. Files Investigational New Drug Application with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory Disorder and Provides Corporate UpdatesJun 01
An unknown buyer entered into an agreement to acquire Cobourg Facility in Cobourg, Ontario from FSD Pharma Inc. (CNSX:HUGE) for CAD 16.5 million.Feb 26